Key Developments: Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

857.90INR
11:38pm EDT
Price Change (% chg)

Rs-0.05 (-0.01%)
Prev Close
Rs857.95
Open
Rs857.90
Day's High
Rs857.90
Day's Low
Rs857.90
Volume
617
Avg. Vol
164,163
52-wk High
Rs867.45
52-wk Low
Rs475.60

Search Stocks

Latest Key Developments (Source: Significant Developments)

Sun Pharmaceutical Industries Ltd to acquire Ranbaxy Laboratories Ltd in $4 billion transaction
Sunday, 6 Apr 2014 10:57pm EDT 

Sun Pharmaceutical Industries Ltd and Ranbaxy Laboratories Ltd:Announced that they have entered into definitive agreements pursuant to which Sun Pharma will acquire 100 pct of Ranbaxy in an all-stock transaction.Under these agreements, Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy.This exchange ratio represents an implied value of `457 for each Ranbaxy share, a premium of 18 pct. to Ranbaxy’s 30-day volume-weighted average share price and a premium of 24.3 pct. to Ranbaxy’s 60-day volume-weighted average share price, in each case, as of the close of business on April 4, 2014.The transaction has a total equity value of about $3.2 billion.  Full Article

Sun Pharmaceutical Industries Ltd hit by FDA ban on Gujarat plant-NDTV Profit
Thursday, 13 Mar 2014 12:51am EDT 

Sun Pharmaceutical Industries Ltd:The U.S. Food and Drug Administration (FDA) has imposed a ban on imports from generic drugmaker Sun Pharmaceutical Industries Ltd's plant at Karkhadi in Gujarat-NDTV Profit.A spokesman for Sun was not available for comment.  Full Article

Sun Pharmaceutical Industries Ltd's subsidiary announces US FDA approval for generic Temodar
Thursday, 13 Feb 2014 10:12am EST 

Sun Pharmaceutical Industries Ltd:Says the US FDA has granted its subsidiary final approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Temodar, Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg.  Full Article

Sun Pharmaceutical Industries Ltd raises FY 2014 revenue guidance - Conference Call
Wednesday, 12 Feb 2014 10:00pm EST 

Sun Pharmaceutical Industries Ltd:Expects consolidated revenues to grow at 29 pct compared to previous guidance of 25 pct growth for FY 2014.  Full Article

Sun Pharmaceutical Industries Ltd Says Issues With USFDA At Caraco Facility Addressed - Business Standard
Monday, 28 Oct 2013 06:00am EDT 

Business Standard reported that Sun Pharmaceutical Industries Ltd has addressed the US health regulator's concerns about manufacturing lapses at its US based Caraco Pharmaceutical Laboratories. United States Food and Drug Administration had conducted inspections in January and May this year and had noticed the lapses. When asked about the nature of lapses and the corrective measures the Company has taken, a Sun Pharmaceutical spokesperson said they were minor observations. The Company has responded to these a long time back, the spokesperson said without elaborating. Earlier in the August 2012, Sun Pharmaceutical Industries had said American health regulator had approved resumption of manufacturing operations at Caraco for two drugs after inspections of facilities. Subsequent to inspections and corrective action, the USFDA had determined Caraco to be in compliance with relevant paragraphs of the consent decree, Sun Pharma had said. Therefore, US Food and Drug Administration (USFDA) had notified that Caraco may resume operations at its manufacturing facility and packaging sites in Detroit and Wixom, Michigan, it added.  Full Article

Sun Pharmaceutical Industries Ltd's Subsidiary And Intrexon Form Joint Venture To Develop New Class Of Therapeutics For Ocular Diseases
Tuesday, 1 Oct 2013 07:21am EDT 

Sun Pharmaceutical Industries Ltd, through its subsidiary and Intrexon Corp announced the formation of joint venture to develop controllable gene-based therapics for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide. The joint venture will leverage Sun Pharma's global capabilities and experience in developing and manufacturing complex dosage forms and specialty pharmaceuticals for niche therapy areas. Intrexon and Sun Pharma will share in both the financing of, and the revenues from, the joint venture. Through an exclusive channel collaboration (ECC), the joint venture will have access to Intrexon's full suite of synthetic biology technologies, including the RheoSwitch Therapeutic System (RTS) platform.  Full Article

Sun Pharmaceutical Industries Ltd's Subsidiary Announces US FDA Approval For Generic Version Of Prevacid
Sunday, 15 Sep 2013 10:33pm EDT 

Sun Pharmaceutical Industries Ltd announced that the US FDA has granted its subsidiary final approval for its Abbreviated New Drug Applications (ANDA) for generic version of Prevacid, Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg.  Full Article

Sun Pharmaceutical Industries Ltd's Subsidiary Secures USFDA Approval For Generic Prandin
Thursday, 11 Jul 2013 10:47pm EDT 

Sun Pharmaceutical Industries Ltd announced that the US FDA has granted subsidiary final approval for Abbreviated New Drug Applications (ANDA) for generic version of Prandin , Repaglinide tablets. Repaglinide tablets, 1 mg and 2 mg are therapeutic equivalents of Novo Nordisk’s Prandin tablets. These tablets have annual sales of approximately USD 200 million in the US. Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.  Full Article

USFDA Gives Nod For Riluzole Tablets To Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd's Glenmark Generics-Business Line
Thursday, 20 Jun 2013 08:00pm EDT 

Business Line reported that Sun Pharmaceutical Industries Ltd and Glenmark Generics have got approval from US health regulator to sell generic versions of nervous system disorder treatment drug Riluzole. As per the United States Food and Drug Administration (USFDA) web site, the approvals were given for generic Riluzole oral tablets in the strength of 50 mg. Riluzole is indicated for treatment of amyotrophic lateral sclerosis.  Full Article

Teva Pharmaceutical Industries Ltd and Sun Pharmaceutical Industries Ltd To Pay $2.15 Billion To Settle Pfizer Inc's and Partner Takeda Pharmaceutical Co Ltd's Patent Suit-Reuters
Wednesday, 12 Jun 2013 09:20am EDT 

Reuters reported that Pfizer Inc said Teva Pharmaceuticals Industries Ltd and Sun Pharmaceutical Industries Ltd would pay $2.15 billion to settle a patent infringement lawsuit related to its acid-reflux drug Protonix. Takeda Pharmaceutical Co Ltd, Pfizer's partner on the drug, will receive 36% or about $774 million from the settlement.  Full Article

India's Ranbaxy Laboratories posts loss in June quarter

MUMBAI, July 29 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by local rival Sun Pharmaceutical Industries Ltd, posted a net loss in the June quarter hit by a one-time provision.

Search Stocks